Pivotal trial of OMS 721 shows efficacy in HSCT-TMA.- Omeros Corp
Read time: 1 mins
Last updated:26th Oct 2020
Published:23th Oct 2020
Omeros Corporation announced final data from its pivotal trial for OMS 721 (narsoplimab) in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved therapy.
Condition: Thrombotic Microangiopathies /HSCT- TMA